Trastuzumab biosimilar in early breast cancer setting: will there be direct patient benefits?
Sign Up to like & getrecommendations! Published in 2017 at "Chinese clinical oncology"
DOI: 10.21037/cco.2017.10.03
Abstract: The inclusion of trastuzumab in the management of both early and metastatic HER2-positive breast cancer has significantly improved survival of these patients and is regarded as a standard of care. However, the cost of 12… read more here.
Keywords: breast cancer; biosimilar early; trastuzumab biosimilar; cancer ... See more keywords